Enzyme replacement therapy for Gaucher's disease (Q41719202)

8 October 2017

1 reference

title

Enzyme replacement therapy for Gaucher's disease (English)

1 reference

enzyme replacement therapy

8 October 2017

0 references

1 reference

Beutler E

1

1 reference

8 October 2017

1 December 1997

1 reference

Best Practice and Research: Clinical Haematology

8 October 2017

1 reference

8 October 2017

10

1 reference

8 October 2017

4

1 reference

8 October 2017

751-763

1 reference

Human beta-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells

8 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Treatment of Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Economic malpractice in the treatment of Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Treatment regimens in Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Failure of alglucerase infused into Gaucher disease patients to localize in marrow macrophages.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

The clinical course of treated and untreated Gaucher disease. A study of 45 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

1 reference

7 January 2021

Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Enzyme Augmentation in Moderate to Life-Threatening Gaucher Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

A less costly regimen of alglucerase to treat Gaucher's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Comparison of magnetic resonance imaging and ultrasound in evaluating liver size in Gaucher patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Pulmonary hypertension in two patients with type I Gaucher disease while on alglucerase therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Individualised low-dose alglucerase therapy for type 1 Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Low-dose versus high-frequency regimens in Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Ceredase dosing concerns for Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Gaucher's Disease of the Lungs

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Glucocerebrosidase treatment of type I Gaucher disease with severe pulmonary involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Low-dose high-frequency enzyme replacement therapy for very young children with severe Gaucher disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

Replacement therapy with imiglucerase for type 1 Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980038-8

7 January 2021

10.1016/S0950-3536(97)80038-8

Identifiers

DOI

1 reference

release_nohsxxtgzvacnogrfloghvhh5e

8 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nohsxxtgzvacnogrfloghvhh5e

24 November 2022

mapped directly with Wikidata item

PubMed ID

9497862

1 reference

PubMed ID

9497862